On 15 January 2015, orphan designation (EU/3/14/1423) was granted by the European Commission to Richardson Associates Regulatory Affairs Ltd, United Kingdom, for synthetic signal peptide of human mucin-1 (amino acids 1-21) for the treatment of plasma cell myeloma.
Synthetic signal peptide of human mucin-1 (amino acids 1-21)
Treatment of plasma cell myeloma
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
|June 2022||The sponsorship was transferred to Turnkey Pharmaconsulting Ireland Limited, Ireland in June 2022.|
|December 2018||The sponsorship was transferred to Richardson Associates Regulatory Affairs Ltd, Ireland, in December 2018.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: